PPARγ激动剂通过抑制经典WNT/β-catenin通路可能治疗孤独症谱系障碍
本文综述提出,在孤独症谱系障碍(ASD)中经典WNT/β-catenin通路活性增加而PPARγ可能降低,两者呈相反作用;PPARγ激动剂通过抗炎作用并抑制该通路,可能对ASD儿童产生有益治疗效果。
要点
- ASD中经典WNT/β-catenin通路增加而PPARγ可能降低,二者作用相反。
- PPARγ激动剂通过抗炎作用及抑制经典WNT/β-catenin通路可能改善ASD。
- 目前ASD无治愈性治疗,药物主要针对共病症状而非核心行为。
核心结论
- PPARγ与经典WNT/β-catenin通路在ASD中呈相反作用,PPARγ激动剂可能成为ASD的治疗选择。
研究设计与样本
- 本文为综述,聚焦PPARγ与经典WNT/β-catenin通路在ASD中相反相互作用的假说及PPARγ激动剂的潜在治疗作用。
主要发现
- ASD中经典WNT/β-catenin通路增加,而PPARγ似乎降低。
- PPARγ激动剂通过抗炎作用对ASD儿童产生有益效果,并在多种病理生理状态下抑制经典WNT/β-catenin通路。
- 经典WNT/β-catenin通路参与中枢神经系统发育,其失调涉及发育性认知障碍。
临床怎么用
- 提示PPARγ激动剂可能作为ASD的潜在治疗方向,需进一步临床研究验证。
局限性
- 本文为综述,未报告原始研究数据或临床试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is characterized by a deficit in social interactions and communication with repetitive and restrictive behavior. No curative treatments are available for ASD. Pharmacological treatments do not address the core ASD behaviors, but target comorbid symptoms. Dysregulation of the core neurodevelopmental pathways is associated with the clinical presentation of ASD, and the canonical WNT/β-catenin pathway is one of the major pathways involved. The canonical WNT/β-catenin pathway participates in the development of the central nervous system, and its dysregulation involves developmental cognitive disorders. In numerous tissues, the canonical WNT/β-catenin pathway and peroxisome proliferator-activated receptor gamma (PPARγ) act in an opposed manner. In ASD, the canonical WNT/β-catenin pathway is increased while PPARγ seems to be decreased. PPARγ agonists present a beneficial effect in treatment for ASD children through their anti-inflammatory role. Moreover, they induce the inhibition of the canonical WNT/β-catenin pathway in several pathophysiological states. We focus this review on the hypothesis of an opposed interplay between PPARγ and the canonical WNT/β-catenin pathway in ASD and the potential role of PPARγ agonists as treatment for ASD.
引用
- Vallée A, Vallée JN, Lecarpentier Y, et al. PPARγ agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/β-catenin pathway. Mol Psychiatry. 2018. PMID: 30104725. doi:10.1038/s41380-018-0131-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。